Original language | English (US) |
---|---|
Article number | e334 |
Journal | Blood cancer journal |
Volume | 5 |
Issue number | 8 |
DOIs | |
State | Published - Aug 14 2015 |
ASJC Scopus subject areas
- Hematology
- Oncology
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: Blood cancer journal, Vol. 5, No. 8, e334, 14.08.2015.
Research output: Contribution to journal › Letter › peer-review
}
TY - JOUR
T1 - Phase I safety data of lenalidomide, bortezomib, dexamethasone, and elotuzumab as induction therapy for newly diagnosed symptomatic multiple myeloma
T2 - SWOG S1211
AU - Usmani, S. Z.
AU - Sexton, R.
AU - Ailawadhi, S.
AU - Shah, J. J.
AU - Valent, J.
AU - Rosenzweig, M.
AU - Lipe, B.
AU - Zonder, J. A.
AU - Fredette, S.
AU - Durie, B.
AU - Hoering, A.
AU - Bartlett, B.
AU - Orlowski, R. Z.
N1 - Funding Information: SZU is a consultant for Celgene, Millennium, Onyx and Sanofi; RZO is a consultant and has received research funding for ArrayBioPharma, Bristol-Myers Squibb, Celgene, Janssen, Millennium, Onyx and Pharmacyclics; SA received honorarium from Millennium. JS is a consultant to Celgene, Millennium, Onyx and Novartis and has received research funding for ArrayBioPharma, Celgene, Millennium, Onyx and Novartis. JV has received speaking honoraria from Celgene and Millennium. The remaining authors declare no conflict of interest. This work was supported by NIH/NCI grants, CA180888, CA180819, CA180858, CA189971, CA189830, CA180835, CA180821, CA31946, CA21076, CA180799, CA21115, CA180820 and in part by Bristol-Myers Squibb Company and Celgene Corporation. Funding Information: This work was supported by NIH/NCI grants, CA180888, CA180819, CA180858, CA189971, CA189830, CA180835, CA180821, CA31946, CA21076, CA180799, CA21115, CA180820 and in part by Bristol-Myers Squibb Company and Celgene Corporation.
PY - 2015/8/14
Y1 - 2015/8/14
UR - http://www.scopus.com/inward/record.url?scp=84975482419&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84975482419&partnerID=8YFLogxK
U2 - 10.1038/bcj.2015.62
DO - 10.1038/bcj.2015.62
M3 - Letter
C2 - 26252787
AN - SCOPUS:84975482419
SN - 2044-5385
VL - 5
JO - Blood cancer journal
JF - Blood cancer journal
IS - 8
M1 - e334
ER -